EMEA-003214-PIP01-22 - paediatric investigation plan

Humanized monoclonal antibody of IgG1 subtype targeting NRP1

Key facts

• Active substance:
  Humanized monoclonal antibody of IgG1 subtype targeting NRP1
• Therapeutic area:
  Ophthalmology
• Decision number:
  P/0283/2022
• PIP number:
  EMEA-003214-PIP01-22
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of diabetic retinopathy
• Route(s) of administration:
  Intravitreal use
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  11/08/2022
• Compliance check done:
  No

Decision

P/0283/2022 : EMA decision on the granting of a product specific waiver for humanised monoclonal antibody of IgG1 subtype targeting NRP1 (EMEA-003214-PIP01-22)

Adopted Reference Number: EMA/629194/2022